Safety and antitumor activity of arsenic trioxide (ATO) plus infusional 5-FU, leucovorin and irinotecan (FOLFIRI) as second-line treatment for refractory metastatic colorectal cancer: Preliminary results from a pilot study

被引：0
|
作者：
Chaudhuri, T. [1 ]
Lakshmaiah, K. C. [1 ]
Babu, K. G. [1 ]
Dasappa, L. [1 ]
Jacob, L. A. [1 ]
Babu, M. C. S. [1 ]
Rudresha, A. H. [1 ]
Lokesh, K. N. [1 ]
Rajeev, L. K. [1 ]
机构：
[1] Kidwai Mem Inst Oncol, Med Oncol, Bangalore, Karnataka, India
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
150P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India
    Lakshmaiah, K. C.
    Chaudhuri, Tamojit
    Babu, Govind K.
    Dasappa, Lokanatha
    Jacob, Linu Abraham
    Babu, Suresh M. C.
    Rudresha, A. H.
    Lokesh, K. N.
    Rajeev, L. K.
    [J]. INDIAN JOURNAL OF CANCER, 2017, 54 (04) : 631 - 633
  • [2] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [3] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [4] Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU
    Iveson, TJ
    Hickish, T
    Schmitt, C
    Van Cutsem, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (13) : 1796 - 1804
  • [5] Phase I study of 5-FU and arsenic trioxide (ATO) in patients with refractory metastatic colorectal carcinoma
    Ardalan, B.
    Subbarayan, P. R.
    Ramos, Y.
    Gonzalez, M.
    Mezentsev, D.
    Reis, I. M.
    Duncan, R.
    Ganjei-Azar, P.
    Lee, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Ting Deng
    Le Zhang
    Xiao-jian Liu
    Jian-ming Xu
    Yu-xian Bai
    Yan Wang
    Yu Han
    Yu-hong Li
    Yi Ba
    [J]. Medical Oncology, 2013, 30
  • [7] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Deng, Ting
    Zhang, Le
    Liu, Xiao-jian
    Xu, Jian-ming
    Bai, Yu-xian
    Wang, Yan
    Han, Yu
    Li, Yu-hong
    Ba, Yi
    [J]. MEDICAL ONCOLOGY, 2013, 30 (04)
  • [8] Weekly irinotecan (CPT-11) as second-line treatment in patients with 5-FU refractory metastatic colorectal cancer.
    Beni, A
    Zidan, J
    Epelbaum, R
    Sikorsky, N
    Michaeli, B
    Skigin, R
    Kuten, A
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 55 - 55
  • [9] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [10] Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC
    Sobrero, Alberto
    Ackland, Stephen
    Carrion, Ramon Perez
    Chiarra, Silvana
    Clarke, Stephen
    Giron, Carlos Garcia
    Langer, Bernd
    Andre, Niko
    Young, Scott
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
12345